Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 août 2010 08h00 HE | Source: Alimera Sciences, Inc.

Photo Release -- Alimera Sciences Announces Key Executive Promotions

ATLANTA, Aug. 16, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
12 août 2010 16h00 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Second Quarter 2010 Financial Results

ATLANTA, Aug. 12, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), today announced financial results for the second quarter ended June 30, 2010 and provided an update on...
29 juil. 2010 08h00 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Hold Conference Call to Discuss Second Quarter 2010 Financial Results

ATLANTA, July 29, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
08 juil. 2010 08h30 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Submits Iluvien(R) MAA for the Treatment of Diabetic Macular Edema

ATLANTA, July 8, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
29 juin 2010 08h00 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Submits Iluvien(R) NDA to the FDA for the Treatment of Diabetic Macular Edema

ATLANTA, June 29, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
03 juin 2010 16h44 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Reports First Quarter 2010 Financial Results

ATLANTA, June 3, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), today announced financial results for the first quarter ended March 31, 2010 and provided an update on...
27 mai 2010 18h23 HE | Source: Alimera Sciences, Inc.

Alimera Announces Iluvien(R) Post 24-Month Visual Acuity Data Indicates Significant Long-Term Improvement in DME

ATLANTA, May 27, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
26 mai 2010 16h05 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Hold Conference Call to Discuss First Quarter 2010 Financial Results

ATLANTA, May 26, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
20 mai 2010 16h00 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at Citi 2010 Global Health Care Conference

ATLANTA, May 20, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
23 avr. 2010 15h19 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Prices Initial Public Offering

ATLANTA, April 23, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM), ("Alimera") today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price...